Loading...

Vectus Biosystems Limited

VBS.AXASX
Healthcare
Biotechnology
A$0.06
A$0.00(0.00%)

Vectus Biosystems Limited (VBS.AX) Company Profile & Overview

Explore Vectus Biosystems Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Vectus Biosystems Limited (VBS.AX) Company Profile & Overview

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.

SectorHealthcare
IndustryBiotechnology
CEOIvan Rajkovic

Contact Information

61 2 9381 1000
3-11 Primrose Avenue, Rosebery, NSW, 2018

Company Facts

IPO DateFeb 22, 2016
CountryAU
Actively Trading

Frequently Asked Questions

;